Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Partially degraded collagen and necrotic dentin matrix proteins comprise a collection of extracellular matrix fragments produced when dentin is exposed to collagenases (e.g., host-derived matrix metalloproteinases or microbial enzymes) and necrotic processes. The mixture includes collagen type I, III, V fragments; degraded non-collagenous proteins like dentin sialophosphoprotein (DSPP), dentin matrix protein 1 (DMP1), osteopontin, glycoproteins, and proteoglycans. These fragments lose normal structural/mineralization functions and may instead act as damage-associated molecular patterns (DAMPs), contribute to inflammation, modulate pulp cell activity, or release sequestered growth factors. They are not a singular, druggable entity but serve as indicators of tissue pathology and remodeling in dental disease.
Not applicable for this fragmented mixture itself. Drugs targeting ECM degradation (e.g., MMP inhibitors) work by inhibiting enzymatic breakdown of matrix proteins, thus reducing the generation of such fragments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Partially degraded collagen and necrotic dentin matrix proteins.